| Trial ID: | L2684 |
| Source ID: | NCT00906529
|
| Associated Drug: |
Levemir (Detemir) And Novolog (Aspart) Insulin
|
| Title: |
Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin
|
| Acronym: |
RASCIN
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Levemir (Detemir) and Novolog (Aspart) Insulin
|
| Outcome Measures: |
Primary: Length of Hospitalization Stay, 18 months | Secondary: Cost of Hospitalization, 18 months|All-Cause Mortality, 18 months|Frequency of Hypoglycemic Episodes, 18 months|Rate of Transfer to Telemetry Unity, 18 months|Rate of Nosocomial Infections, 18 months|Rate of Surgical Procedures, 18 months|Rate of Re-hospitalization, 18 months|Time to goal blood glucose level, 18 months|Time to becoming medically stable for discharge, 18 months
|
| Sponsor/Collaborators: |
Sponsor: University of Texas Southwestern Medical Center | Collaborators: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-05
|
| Completion Date: |
2011-03
|
| Results First Posted: |
|
| Last Update Posted: |
2019-01-16
|
| Locations: |
Parkland Memorial Hospital, Dallas, Texas, 75235, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00906529
|
